Hikal Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹434 crore for the second quarter of FY27. EBITDA stood at ₹45 crore with a margin of 10.3%. The net loss after tax (PAT) for the quarter was ₹6 crore.
Hikal Announces Q2 FY27 Financial Results
Hikal Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The company has reported a consolidated revenue of ₹434 crore for the second quarter of the financial year 2027 (Q2 FY27). This marks a significant increase compared to the previous periods.
Consolidated Performance Highlights
The consolidated performance for Q2 FY27 shows a robust revenue figure of ₹434 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter stood at ₹45 crore, reflecting an EBITDA margin of 10.3%. For the same quarter, the Profit After Tax (PAT) was reported as ₹(6) crore.
Comparing to the previous financial year’s second quarter (Q2 FY26), revenue for Q2 FY27 has seen substantial growth. In Q2 FY26, revenue was ₹319 crore, EBITDA was ₹7 crore, and PAT was ₹(35) crore. The EBITDA margin in Q2 FY26 was 2.3%.
Segment-wise Revenue Split
Hikal’s revenue split between its key business segments for Q2 FY27 shows the Pharmaceuticals division contributing 278 crore (64% of total revenue), and the Crop Protection segment contributing 156 crore (36% of total revenue). This compares to Q1 FY27 where Pharmaceuticals generated 233 crore (58%) and Crop Protection 170 crore (42%). In Q2 FY26, Pharmaceuticals revenue was 190 crore (59%) and Crop Protection was 129 crore (41%).
Performance Commentary
The company highlighted several key achievements for Q2 FY27. Quarterly revenue grew by 36%, driven by recovery in the established API portfolio and continued CDMO execution. EBITDA margins improved to 10.3%. Pharmaceuticals revenue grew by 47% YoY to ₹278 crore, supported by API volume recovery and expansion in the customer pipeline. Crop Protection revenues stood at ₹156 crore, growing 21% YoY, despite operating challenges. The company also mentioned signing a multi-year CDMO contract with a Europe-based global agrochemical company and the commencement of commercial production at its new facility in Panoli for its Personal Care business.
Sameer Hiremath, Chairman & MD, commented that Q2 FY2027 reflected a recovery with improving performance in Pharmaceuticals and ongoing efforts to strengthen the Crop Protection business. He expressed confidence in the growth outlook for H2 and reiterated full-year guidance of mid-teen growth in revenue and substantial improvement in profitability.
Source: BSE
